The ability to screen for trauma symptoms in certain high-risk populations could soon benefit from biomarker data gathered through wearable devices, according to a new study.
Reduced 24-hour activity variance and changes in both rest activity measures and in total sleep transitions have been linked to changes in markers of pain and its endurance over time, in sleep patterns, and in symptoms of anxiety following an investigation that gathered biomarker data on recovery and traumatic stress exposure via wrist-wearable technology.
These new study findings were published in JAMA Psychiatry, with the authors noting, “We derived and validated cross-sectional and longitudinal associations between 24-hour activity patterns and adverse posttraumatic neuropsychiatric sequelae (APNS) symptoms during the 8 weeks following a traumatic event, a high-risk period during which individuals transition to symptom recovery or persistence. To our knowledge, this study is the first to examine such associations.”
Their investigation was a subanalysis of data from the AURORA study of patients seen at 27 emergency departments (EDs) after exposure to traumatic stress. Of the 3040 who met initial study inclusion criteria—aged 18 to 65 years, could speak and read English, and had arrived at an ED within 72 hours of experiencing trauma, such as a car collision, physical assault, sexual assault, a fall from more than 10 feet, and mass casualty incidents—2021 patients provided device data and were included in this 8-week assessment and analysis; their mean (SD) age was 35.8 (13.0) years and the most common annual income was less than $35,000. In addition, most patients were female (62.2%), Black (50.2%), did not have a college degree (79.3%), and ended up in the ED because of a vehicle collision (75.2%).
The 8 biomarkers evaluated for symptoms of posttraumatic neuropsychiatric sequelae were pain (24-hour activity variance and percent of awake time in 24 hours), somatic symptoms (percent of awake time in 24 hours and total sleep transitions), depressive symptoms, hyperarousal, and nightmares (percent of awake time in 24 hours and total sleep transitions). Of these, reduced 24-hour activity variance was associated with greater pain severity (r = –0.14; 95% CI, –0.20 to –0.07).
In addition, changes in 6 rest activity measures were associated with changes in pain over time, and changes in the number of transitions between sleep and wake over time were associated with changes in pain, sleep, and anxiety. Furthermore, these device biomarkers identified individuals with good recovery for pain (positive predictive model [PPV], 0.85; 95% CI, 0.82-0.88), sleep (PPV, 0.83; 95% CI, 0.59-0.67), and anxiety (PPV, 0.76; 95% CI, 0.72-0.80).
Overall, the researchers identified that reduced activity variance was a biomarker for increased pain, as well as 9 other rest-activity biomarkers that changed with APNS symptoms over time.
Six activity-related biomarkers changed with pain, and 1 sleep-related biomarker was associated with changes in pain, sleep, and anxiety symptoms over time. Participants who experienced worsening pain showed increasing number of transitions between wake and sleep.
The researchers acknowledged that this study had certain limitations, including that the generalizability of their findings to patients who do not go to the ED is unknown and that missing or inaccurate self-reported data may not have been accounted for in their findings. The researchers believe that future studies should also examine patients wearing wrist devices over a longer period of time, and not just for the 8 weeks following a traumatic event.
Despite some limitations and uncertainties, the researchers believe that wrist-wearing devices can facilitate the collection of data on potential biomarkers for identifying adverse changes in pain, sleep, and anxiety symptoms in patients after a traumatic event.
“In the future, such biomarkers might be useful to identify trauma survivors who merit further evaluation for adverse trauma outcomes, particularly in vulnerable populations,” wrote the researchers. “Such biomarkers might also be useful to help clinicians and patients evaluate their responses to treatment interventions for pain, sleep, or anxiety and to help patients understand how their activity, rest, and sleep affect their health.”
Reference
Straus LD, An X, Ji Y, et al. Utility of wrist-wearable data for assessing pain, sleep, and anxiety outcomes after traumatic stress exposure. JAMA Psychiatry. Published online January 11, 2023. doi:10.1001/jamapsychiatry.2022.4533
AI Tool Shows Promise for Faster, More Accurate Autism and ADHD Diagnoses
July 8th 2025Participants performed touchscreen-based reaching tasks while wearing wireless motion sensors, which recorded linear acceleration, angular velocity, and roll-pitch-yaw orientation at millisecond resolution.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Practical Considerations for AI in Community Oncology
July 8th 2025Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining operations, while addressing challenges in data accuracy and equity, said speakers at the Tennessee Oncology “Tech Innovations in Community Oncology."
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
How AI Can Address the Troubled Business Model in Oncology
July 7th 2025Artificial intelligence (AI) will transform community oncology, addressing workforce shortages and reimbursement challenges while enhancing patient care and operational efficiency, discussed speakers at Tennessee Oncology's “Tech Innovations in Community Oncology."
Read More
At ASCO, Testing and AI Rival Drugs for Attention, but Reimbursement Remains a Barrier
July 5th 2025Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage cancer care over time. A feature from our upcoming special issue of Evidence-Based Oncology: our annual ASCO recap.
Read More
AI Tool Shows Promise for Faster, More Accurate Autism and ADHD Diagnoses
July 8th 2025Participants performed touchscreen-based reaching tasks while wearing wireless motion sensors, which recorded linear acceleration, angular velocity, and roll-pitch-yaw orientation at millisecond resolution.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Practical Considerations for AI in Community Oncology
July 8th 2025Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining operations, while addressing challenges in data accuracy and equity, said speakers at the Tennessee Oncology “Tech Innovations in Community Oncology."
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
How AI Can Address the Troubled Business Model in Oncology
July 7th 2025Artificial intelligence (AI) will transform community oncology, addressing workforce shortages and reimbursement challenges while enhancing patient care and operational efficiency, discussed speakers at Tennessee Oncology's “Tech Innovations in Community Oncology."
Read More
At ASCO, Testing and AI Rival Drugs for Attention, but Reimbursement Remains a Barrier
July 5th 2025Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage cancer care over time. A feature from our upcoming special issue of Evidence-Based Oncology: our annual ASCO recap.
Read More
2 Commerce Drive
Cranbury, NJ 08512